Allogene Therapeutics, Inc. (ALLO) Operating Margin
- Operating margin · 12 months: Value -3886.14%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -3886.14% | Operating income / revenue. Period ending 2026-06-30. $-180.32M ÷ $4.64M × 100 ≈ -3886.14% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -180.32M USD | Operating Income (Loss) |
| Revenue | 4.64M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 122.52M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-180.32M | $4.64M | (m) | $122.52M | (m) | -3886.14% |
| 2026-03-31 | $-190.22M | (m) | (m) | $131.96M | (m) | (m) |
| 2025-12-31 | $-209.31M | $0.00 | (m) | $150.15M | (m) | (m) |
| 2025-09-30 | $-227.40M | $0.00 | (m) | $166.49M | (m) | (m) |
| 2025-06-30 | $-254.27M | $0.00 | (m) | $180.04M | (m) | (m) |
| 2025-03-31 | $-268.89M | $0.00 | (m) | $190.24M | (m) | (m) |
| 2024-12-31 | $-273.20M | $22.00K | (m) | $192.30M | (m) | -1241813.64% |
| 2024-09-30 | $-297.82M | $43.00K | (m) | $201.99M | (m) | -692600.00% |
| 2024-06-30 | $-289.04M | $65.00K | (m) | $203.25M | (m) | -444676.92% |
| 2024-03-31 | $-298.15M | $87.00K | (m) | $214.94M | (m) | -342700.00% |
| 2023-12-31 | $-327.74M | $95.00K | (m) | $242.91M | (m) | -344986.32% |
| 2023-09-30 | $-338.94M | $186.00K | (m) | $263.67M | (m) | -182224.19% |
| 2023-06-30 | $-358.45M | $192.00K | (m) | $281.34M | (m) | -186693.23% |
| 2023-03-31 | $-354.53M | $234.00K | (m) | $276.47M | (m) | -151507.26% |
| 2022-12-31 | $-335.45M | $243.00K | (m) | $256.39M | (m) | -138044.86% |
| 2022-09-30 | $-312.97M | $247.00K | (m) | $234.95M | (m) | -126707.69% |
| 2022-06-30 | $-308.15M | $247.00K | (m) | $230.03M | (m) | -124756.28% |
| 2022-03-31 | $-302.58M | $205.00K | (m) | $225.15M | (m) | -147601.46% |
| 2021-12-31 | $-255.79M | $38.49M | (m) | $220.18M | (m) | -664.58% |
| 2021-09-30 | $-251.26M | (m) | (m) | $218.42M | (m) | (m) |
| 2021-06-30 | $-241.63M | (m) | (m) | $211.12M | (m) | (m) |
| 2021-03-31 | $-233.76M | (m) | (m) | $206.13M | (m) | (m) |
| 2020-12-31 | $-258.24M | (m) | (m) | $192.99M | (m) | (m) |
| 2020-09-30 | $-253.46M | (m) | (m) | $190.12M | (m) | (m) |
| 2020-06-30 | $-240.43M | (m) | (m) | $178.69M | (m) | (m) |
| 2020-03-31 | $-223.23M | (m) | (m) | $163.17M | (m) | (m) |
| 2019-12-31 | $-202.01M | (m) | (m) | $144.53M | (m) | (m) |
| 2019-09-30 | $-170.48M | (m) | (m) | $113.68M | (m) | (m) |
| 2019-06-30 | $-137.66M | (m) | (m) | $84.55M | (m) | (m) |
| 2019-03-31 | $-226.71M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-192.84M | (m) | (m) | $151.86M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |